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Caregivers of HIV-positive children were interviewed in the Mbarara and Isingiro districts of Uganda to 
identify current trends in practices related to HIV testing and the disclosure of HIV status to the child. A 
total of 28 caregivers of at least one HIV-positive child participated in semi-structured interviews exploring 
when and why they tested the child for HIV, when the child was informed of their positive status, and what 
the caregiver did to prepare themselves and the child for status disclosure. For nearly all (96%) respondents, 
the decision to test the child for HIV was due to existing illness in either the child or a relative. Major 
themes identified included caregivers stressing medication adherence when informing the child of their 
positive status and doubt that the children truly understood what was being explained to them when their 
status was disclosed. Most (65%) children were informed of their HIV status between the ages of 5 and 9, 
with the mean age of disclosure occurring at the age of 7 (±2) years. Caregivers reported that children began 
to learn about HIV at the same age they were informed of their positive status, and as many as two thirds 
(64%) of the caregivers sought advice from an HIV counsellor prior to disclosure. 45% of caregivers 
admitted to initially telling the child that they had a disease other than HIV, and this period of deceiving 
the child had a mean length of 3 (±2) years. 79% of caregivers reported that a child would be discriminated 
against in their community if the community learned of their HIV status, and 64% agreed that a child would 
feel that their life was without hope if they became aware of their HIV status. These findings suggest that 
while the age of HIV status disclosure in this setting is similar to what is recommended by current 
guidelines, the HIV disclosure experience in Mbarara and Isingiro districts  differs with respect how 
caregivers prepare themselves and the child, and approaching disclosure as an ongoing process. The doubts 
expressed by caregivers regarding the child’s level of HIV understanding following the disclosure 
experience suggest the children may be insufficiently prepared at the time of the initial disclosure event. 
The findings also suggest that examining the content of pre-disclosure counselling and HIV education, and 
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Chapter 1: Research Aims 
Research Aims 
The aim of this study was to interview primary caregivers of HIV positive children to identify trends 
related to the age of HIV testing and disclosure, how caregivers prepared themselves and the child prior 
to initiating disclosure, the methodology of disclosure, and caregivers’ impressions of the effects and 




Chapter 2: Literature Review 
2.1 HIV in Uganda 
Uganda is in the unique position to be an effective prototype for other Sub-Saharan African countries since 
it has one of the most mature HIV epidemics worldwide, and is one of the first countries to stabilize its HIV 
epidemic (Kahanen 2008). Currently, Uganda is home to an estimated 1.2 million people living with HIV 
(including 150,000 children), an estimated 1.2 million orphans due to HIV, and a national HIV prevalence 
among adults aged 15 to 49 of 7.2% (UNAIDS 2012). By contrast, the hardest-hit of the Sub-Saharan 
African nations can have HIV prevalence rates as high as 20%, with significantly higher rates of HIV 
incidence, mother to child transmission, and child mortality due to AIDS (UNAIDS 2010). For this reason, 
the challenges encountered by Uganda today may likely be encountered in the future by other nations as 
their own HIV epidemics stabilize. Likewise, research into HIV management and counselling strategies in 
Uganda may yield data that prove useful in future health policy development in other nations. The Mbarara 
and Isingiro districts in western Uganda are particularly attractive sites in which to conduct HIV research: 
their HIV prevalence has historically been greater than the nation overall and has an HIV prevalence most 
recently estimated at 8.0% (Government of Uganda 2014) and they possesses a variety of both remote rural 
and municipal settlements. 
2.2 Children with HIV in sub-Saharan Africa 
As the global HIV epidemic enters its fourth decade, significant advances have been made in HIV 
prevention and treatment in sub-Saharan Africa. While sub-Saharan Africa remains the hardest-hit region 
(accounting for the majority of HIV-related deaths, new HIV infections, and greatest HIV prevalence 
worldwide), the outlook for the area is beginning to show signs of improvement. Currently, sub-Saharan 
Africa is home to an estimated 24.7 million HIV-positive people, including 2.9 million children (UNAIDS 
2014).  
Improved HIV education and increased access to antenatal care have been credited with reducing the 
number of new infections reported annually, with an overall reduction of 45% in new HIV infections among 
children (UNAIDS 2014). This increasing access to antiretroviral drug therapies have reduced the number 
of HIV-related deaths (WHO 2013a). It is estimated that, in 2013, 34% of people in low and middle-income 
countries who required antiretroviral therapy (ART) were able to access it (UNAIDS 2013). Further, in 
2013, 240,000 new HIV infections among children were recorded – a 58% drop in the HIV incidence rate 




accessibility of vital medication and education to low-income, high-burden areas continue apace, new 
challenges to HIV-related health promotion continue to present themselves. 
One such challenge involves the increased proportion of HIV infected children who live through to 
adolescence due to increased access to life-saving drug therapies (Brady et al. 2010). As these children 
mature, the question of when and how they should be made aware of their diagnosis is raised.  
2.3 Pediatric HIV Treatment Guidelines 
Current WHO recommendations for HIV prevention, diagnosis and treatment stress the importance of early 
detection of the disease in at-risk children (WHO 2008). Initiating ART by 12 weeks of age in HIV positive 
children reduces HIV-related mortality by 75% (Violari et al. 2007). As stated above, it is estimated that 
50% of all HIV positive infants who do not receive treatment with antiretroviral and antibiotic medications 
will die before reaching the age of two years old. For this reason, the WHO recommends HIV testing at 4 
to 6 weeks of age for all children who are born to HIV positive mothers (WHO 2010a). If the child tests 
negative, a follow-up test at 18 months is also recommended to determine whether HIV was transmitted 
later, via breast milk (WHO 2010a, WHO 2006). Further, HIV testing and counselling is also recommended 
for all children presenting with below average growth or malnutrition in areas that are suffering from 
generalized epidemics (WHO 2010a). The overall goal of these guidelines is to permit initiation of 
treatment of the infected children before clinical signs of advanced infection present themselves. 
Respiratory infections such as Pneumocystis pneumonia (PCP) is the most common cause of death among 
HIV positive infants (WHO 2006). For this reason, prophylactic use of co-trimoxazole is one of the most 
common drug therapies for HIV-positive children. A combination of sulfamethoxazole and trimethoprim, 
the antibiotic has activity against many pathogens that opportunistically infect the lungs of HIV positive 
individuals. The WHO currently recommends co-trimoxazole prophylaxis for all HIV-exposed infants from 
4-6 weeks of age until they are confirmed to be HIV negative and are no longer being exposed to potential 
sources of infection such as breast milk from an infected mother (WHO 2006). In infants that are found to 
be HIV positive, co-trimoxazole is recommended until at least one year of age (WHO 2006). For children 
over 1 year old, the decision to initiate or continue co-trimoxazole is made based on CD4 cell count or the 
stage of infection (WHO 2006). Randomized controlled trials have established the efficacy of co-
trimoxazole therapy in reducing morbidity and mortality of infants and children with HIV (Chintu et al. 
2004).  
Antiretroviral therapy is another key HIV treatment that has been shown to slow the progression of HIV 




(Fassinou et al. 2004, Mermin et al. 2008). Current WHO guidelines recommend ART to be initiated in all 
children infected with HIV below 5 years of age, regardless of WHO clinical stage or CD4 cell count (WHO 
2013b). For children 5 years of age and older, all children with CD4 cell counts of 500 cells/mm3 or less, 
regardless of clinical stage, are also recommended to receive ART (WHO 2013b). It is also recommended 
by the WHO that any children infected with HIV with severe or advanced symptomatic disease (WHO 
stages 3 or 4) receive ART regardless of CD4 count (WHO 2013b). Finally, it is recommended by the WHO 
that ART be initiated in any child younger than 18 months who has received a presumptive clinical 
diagnosis of HIV (WHO 2013b). 
The above-cited guidelines recommend an ART regimen consisting of lopinavir and ritonavir (LPV/r) for 
all HIV positive children younger than 3 years of age. Nevirapine (NVP) – based regimens are the preferred 
alternative if LPV/r is not feasible (WHO 2013b). These general recommendations change to a abacavir 
(ABC), lamivudine (3TC) and zidovudine (AZT) regimen in the event that they have active tuberculosis 
(TB), reverting to the prior regimen once the duration of the TB treatment has elapsed (WHO 2013b). For 
children 3 years of age and older, efavirenz (EFV) is the preferred non-nucleoside reverse transcriptase 
inhibitor (NNRTI), while NVP is the preferred alternative. Adolescent ART recommendations align with 
adult regimens, typically consisting of either tenofovir (TDF), AZT or ABC in combination with 3TC 
(WHO 2013b). 
In order to receive the benefits of ART, patients must maintain near perfect adherence to the therapy. 
Compliance rates below 90% have been associated with increased frequency of drug resistance and 
increased risk of opportunistic infections (Vreeman et al. 2008). The need for high adherence rates can be 
impeded by the challenging nature of the regimens themselves; requiring multiple medications to be taken 
multiple times per day increases the risk of missed or delayed doses (Brogley et al. 2005). Additionally, 
pediatric HIV infection is often associated with cognitive delays and depression, which are also predictive 
of reduced rates of adherence (Brown et al. 2000). In addition to these factors, the child’s knowledge of 
their HIV infection, or lack thereof, is another factor with the potential to influence a child’s adherence to 
ART (Williams et al. 2006, Paterson et al. 2000, Chi-Ling and Rosemary 1999).  
2.4 HIV Testing of Children in sub-Saharan Africa 
It is currently estimated that less than half (48%) of people with HIV know their status (UNAIDS 2014). 
The WHO recommends that, in areas with generalized epidemics, testing and counselling that is linked to 
prevention, treatment and counselling, be available not only in provider-initiated settings but also be 
available in the wider community (WHO 2013b). In spite of these recommendations, many barriers to HIV 
testing exist, especially where children are concerned. Often, the child has never been tested for HIV due 
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to a lack of access to testing services or reluctance on the part of caregivers to get the child tested; indeed, 
current research suggests that those who are most likely to benefit from HIV testing services and drug 
therapies, especially in rural or low-income areas, are typically not receiving them (WHO 2010b). A recent 
Ugandan study has suggested that, for the majority of caregivers of HIV-positive children, the decision to 
test the child for HIV occurs only after the child begins exhibiting symptoms of illness (Rwemisisi et al. 
2008). 
In other cases, the testing of children who are exposed to HIV is delayed due to a perceived lack of benefit 
versus risks involved – the typical progression of the disease in untreated children can lead to the belief that 
children who are infected are beyond help. Currently, the majority of HIV positive children are diagnosed 
only when they begin experiencing severe illness, and thus have a poorer prognosis than those diagnosed 
while asymptomatic (Rwemisisi et al. 2008, Kline 2006). Further, recent studies have shown that parents 
and caregivers are reluctant to have children tested out of fear of the emotional impact a positive diagnosis 
would have on the parents themselves, as well as uncertainty over what benefits would exist from knowing 
the child’s HIV status (Vreeman et al. 2010). These attitudes were especially common for parents of 
younger children that were years from sexual maturity and thus considered to be at low risk of spreading 
the disease if they were, in fact, HIV positive. The study also suggested that these attitudes toward the 
testing of children were related, at least in part, to inconsistencies in recommendations for the testing of 
children. These inconsistencies in the recommendations have only been remedied and communicated to 
patients in sub-Saharan Africa in the past decade (Uganda Ministry of Health 2005). 
The elimination of mother-to-child transmission of HIV by 2020 is a target of UNAIDS’ 2016-2021 strategy 
(UNAIDS 2015a), and in Uganda a reduction in annual HIV incidence among children from 27,660 to 
9,629 has been observed between 2011 and 2013 (Government of Uganda 2014). It has been estimated that 
94% of expectant mothers attending antenatal clinics in Uganda received counselling and testing for HIV 
in 2011 (AVERT 2015). Recent efforts to scale-up the elimination of mother-to-child transmission resulted 
in 77% of positive mothers in 21 Global Plan Priority countries receiving ARV’s (UNAIDS 2015b). It is 
estimated that 20% of new HIV infections in Uganda are due to mother-to-child transmission, although this 
may be significantly higher since many births in Uganda occur in rural areas outside of healthcare centres 
(AVERT 2015). Even if mother-to-child transmission of HIV had been eliminated entirely in Uganda by 
2015, the Ugandan Ministry of Health projected that as many as 176,948 children under 15 with HIV would 
remain (Government of Uganda 2014) and would still require appropriate disclosure of their HIV status. 
Should the goal of zero mother-to-child transmission by 2020 become a reality, the issue of disclosure of 





2.5 Disclosure of Diagnosis to HIV Positive Children 
As an increasing proportion of HIV infected children live through school age and into adolescence due to 
increased access to life-saving drug therapies, the issue of HIV status disclosure becomes increasingly 
relevant (Brady et al. 2010). As these children mature, the question of when and how they should be made 
aware of their diagnosis is raised. For those that have been tested, many HIV-positive children are not 
informed of their status (Kouyoumdjian et al. 2005, Waugh 2003) and are ultimately unaware of their HIV 
status even if currently receiving treatment (Flanagan-Klygis et al. 2002).   
A 2012 literature review of articles published between 1996 and 2012 found that the average rate of HIV 
status disclosure to positive children was 29.5% overall, with studies taking place in industrialized 
countries, predominantly the United States, having disclosure rates over twice that of low-to-middle income 
countries, predominantly in sub-Saharan Africa (Vaz et al. 2008, Pinzón-Iregui et al. 2012). The review 
identified many common threads in the 15 year span of literature, including a lack of support and guidance 
for caregivers with respect to the disclosure process and a need for evidence-based guidelines. Although 
one would expect the disclosure rates to trend upward in more recent studies, the rates reported in the more 
recent studies set in low-to-middle income countries still ranged from as low as 3% to a high of only 41% 
(Vreeman et al. 2010, Weiner et al. 1994, Oberdorfer et al. 2006, Menon et al. 2007, Bhattacharya et al. 
2010). A more recent systematic review focused solely on resource-limited settings (Vreeman et al. 2012) 
showed similar disclosure rates while identifying that HIV status disclosure was typically viewed by 
caregivers as a one-time event as opposed to an ongoing process. A recent study in South Western Uganda 
suggests that only 31% of HIV positive children age 15-17 have been informed of their HIV status, while 
nearly half of the children are completely unaware of their condition (Atwiine et al. 2014). Common barriers 
to disclosure identified in this review included fear that the child would disclose his or her HIV status to 
others, stigma, fear of stigma, concern for the child’s emotional or physical health, belief the child was not 
ready or too young, and a feeling of being unprepared for the disclosure process or event (Kiwanuka et al. 
2014, Vaz et al. 2010). 
To date, the majority of research into the disclosure of a diagnosis of long-term, potentially fatal disease 
has involved chronic diseases such as cancer as opposed to HIV (Katz and Jau 1984, Slavin et al. 1982, 
Beale et al. 2005), and many of the HIV disclosure guidelines that currently exist are derived from such 
work (New York State Department of Health AIDS Institute 2009). These guidelines recommend HIV 
counsellors and other health care professionals work with the caregiver to develop a ‘disclosure plan’ that 




Department of Health AIDS Institute 2009). The most recent guidelines published by the WHO recommend 
that children of school age have their positive status disclosed to them, with younger children being 
informed incrementally as they mature; however, the quality of evidence upon which these 
recommendations are based is noted to be ‘low’ (WHO 2011). More recently, a formal disclosure 
framework based on the child’s stage cognitive development has been proposed in the United States 
(Cantrell et al. 2013). 
These recommendations are based on research drawing on Piaget’s theory of cognitive development 
(Bibacu and Walsh 1980). Specifically, research into children’s understanding of concepts of illness and 
disease states that children in the Concrete Operational stage of development, as described by Piaget (Piaget 
1952) are capable of understanding concept of illness and how an illness affects the body (Bibacu and 
Walsh 1980, Lipson 1993). Occurring approximately between the ages of 7 and 11, children in the Concrete 
Operational stage are characterized by an increase in logical thought, including the logical ability known 
as conservation (Piaget 1952). Conservation refers to the understanding that properties of an object remain, 
or are conserved, even when other properties change (Piaget 1952). A classic example to test for 
Conservation involves showing the child two identical glasses filled with equal volumes of water, getting 
the child to confirm that the volumes are equal, and then transferring the water from one glass into a pair 
of taller and thinner glasses. A child exhibits conservation if he or she is able to recognize that the new 
vessels contain the same amount of water as the original vessel (Piaget 1952). 
Although researchers have identified the Concrete Operational stage as the optimal time to disclose a 
diagnosis to a child (Bibacu and Walsh 1980), it is possible that current guidelines overlook important 
characteristics of many HIV positive children. As mentioned above, the most recently published World 
Health Organization guidelines on HIV testing and disclosure recommend disclosure to all children aged 
6-12 while younger children should be informed of their status “incrementally to accommodate their 
cognitive skills and emotional maturity” (WHO 2011). Currently, 91% of all HIV positive children live in 
Sub-Saharan Africa (UNAIDS 2014), a region that differs greatly from where Piaget conducted his 
research. Up to 50% of children initiated on ARV therapy in African HIV treatment programs are 
undernourished (Balton-Moore et al. 2007). Severe malnutrition, sufficient to cause stunted growth, is 
linked to structural and functional damage to the brain, which may delay cognitive development (Dewy and 
Begum 2011). Even in situations where malnutrition is not severe, early nutritional intake is a predictor of 
later cognitive ability (Freeman et al. 1980, Sigman et al. 1991). For these children, the standard 
recommendation of disclosure at ‘school age’ may result in disclosure too early for them to reasonably 
understand. This issue may be compounded if an attempt were made to disclose to even younger children, 




ensure that they are in the Concrete Operational stage prior to enacting their disclosure plan, it is even 
possible that current best practices would not produce the best outcomes for children in Sub-Saharan Africa. 
Factors including the age of the child at the time of disclosure, method of disclosure, and involvement of 
health care professionals or counsellors could conceivably affect whether the disclosure process is 
beneficial and empowering or traumatic (Flanagan-Klygis et al. 2002, Vaz et al. 2010, Lipson 1993). The 
Uganda Ministry of Health’s most recently published guidelines recommend that counsellors determine 
whether the caregiver is willing to discuss HIV and the test results before counselling is initiated, and that 
counsellors work with the caregivers of an HIV-positive child to plan for the child’s future care (Uganda 
Ministry of Health 2003).  
Although it seems logical that the manner by which an HIV-positive child learns his or her HIV status 
would have significant repercussions on the child’s psychological state, medication compliance, and overall 
well-being, minimal research into this question has been conducted in the developing world. Research 
performed in Sub-Saharan Africa suggests that disclosure of HIV status is often viewed as a discrete event, 
as opposed to a process (Atwiine et al. 2014, Kiwanuka et al. 2014), but to date few studies in Uganda or 
elsewhere in sub-Saharan Africa have examined how caregivers choose to prepare themselves and the child 
prior to disclosure. 
Interviews with health care professionals reveal a common belief that non-disclosure can lead to a change 
in adherence to daily medication regimens (Mellins et al. 2002), and increased depression and anxiety 
among children infected with HIV (Flanagan-Klygis et al. 2002, Bikaako-Kajora et al. 2006), but the 
evidence to date in sub-Saharan Africa remains statistically insignificant (Uganda Ministry of Health 2003) 
and highly subjective Vreeman et al. 2010, Bikaako-Kajora et al. 2006). Other research has examined the 
many potential barriers to disclosure for caregivers of HIV-positive children: focus groups of primary 
caregivers in South Africa identified stigma, lack of knowledge and communication skills related to HIV, 
and emotional unpreparedness as factors leading to an overall lack of comfort discussing HIV with the 
positive children under their care (Kouyoumdjian et al. 2005) The fear of stigma, in particular, is often cited 
as a major barrier to disclosure of a child’s HIV status. As the majority of HIV-positive children were 
infected perinatally, biological parents of HIV-positive children have reported concern that their child 
would blame them (Kouyoumdjian et al. 2005, Oberdorfer et al. 2006). Similarly, many parents of HIV-
positive children are reluctant to disclose the diagnosis to the child in order to protect them from the stress 
of keeping such a secret from the community and to spare them the emotional trauma of knowing that they 
are suffering from a terminal disease (Waugh 2003).  
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Research investigating the results of disclosing the HIV diagnosis to positive children has, to date, produced 
positive results. A 2007 study investigating Romanian children and teens identified an association between 
a lack of HIV status knowledge and disease progression up to and including death (Ferris et al. 2007). Other 
studies conducted in industrialized countries indicate that children who are aware of their positive status 
fare better in terms of medication compliance, coping mechanisms, and overall well-being than children 
who are unaware of their HIV status (Vaz et al. 2008, Weiner et al. 1994, Ferris et al. 2007, Blasini et al. 
2004).  
A recent study in Southwestern Uganda suggests that only 31% of children aged 5-17 have been informed 
of their HIV status, while nearly half of the children are completely unaware of their condition (51). HIV 
status knowledge has implications with respect to drug compliance, health behaviours, and the child’s 
overall prognosis (Lipson 1993), but many hospitals in Uganda currently lack formal policies and 
procedures for disclosing a positive HIV diagnosis to a child (Rwemisisi et al. 2008, Mellins et al. 2002). 
Another study of 42 HIV positive children and their caregivers at the Mildmay HIV/AIDS centre in 
Kampala investigated whether a link existed between a child’s adherence to their HIV medication and 
whether their HIV infection has been disclosed to them (Bikaako-Kajura et al. 2006). Over the course of 
semi-structured interviews lasting 1-3 hours, the researchers found that only 29% of the children had been 
informed of their HIV status, 38% were unaware of their specific diagnosis but were deemed as having 
‘partial disclosure’ – the knowledge that they had an illness of some kind – and 33% were completely 
unaware of any illness. Children who were aware of their HIV status exhibited increased rates of self-
reported adherence to drug therapy, whereas children who were never informed were more likely to report 
lapses in their adherence. Further, a lack of disclosure was often associated with intentional non-adherence 
to HIV-related drug regimens once the child finally learned the truth. 
These results appear consistent with those from other studies conducted in Africa (Vaz et al. 2008, Balton-
Moore et al. 2007), Thailand (Oberdorfer et al. 2006) and the developed world (Weiner et al. 1994, Blasini 
et al. 2004), There remains, however, a lack of evidence in sub-Saharan Africa to determine optimal timing 
and methodology of HIV disclosure. Just as importantly, there has been little research into how the 
disclosure process typically unfolds in Uganda and how effective it is in the eyes of stakeholders. Thus, the 
aim of this study was to interview primary caregivers of HIV-positive children using a qualitative 
methodology to identify trends related to the age disclosure occurs, how caregivers prepare themselves and 
the child for the disclosure process, exactly how this process occurs, and the challenges faced during the 
testing and disclosure process. This information can then be used to determine what ‘best-practice’ looks 








Chapter 3: Methods and Study Design 
3.1 Ethics Approval 
This study was approved by the University of Saskatchewan’s Behavioural Research Ethics Board, the 
Mbarara University Institutional Research Ethics Committee (MUST-IREC) and the Uganda National 
Council for Science and Technology.  
3.2 Selection and Recruitment of Caregivers 
The study evaluated qualitative data collected from interviews with caregivers of HIV- positive children in 
the Mbarara and Isingiro districuts in Uganda, recruited from Mbarara University of Science and 
Technology (MUST) Immune Suppression Syndrome (ISS) clinic and at parish meetings for the Foundation 
for AIDS Orphaned Children (FAOC). All caregivers presenting for routine visits at the ISS clinic were 
screened against the inclusion criteria by nursing staff. Each eligible caregiver was approached in the 
waiting area and invited to participate in an interview to be conducted in a private room within the ISS 
clinic. In rural parishes of Isingiro district, FAOC beneficiaries were addressed by FAOC staff at monthly 
parish meetings; the study was announced verbally in English, Runyankole and Luganda (where 
appropriate) to attendees of the meetings. Attendees were provided with contact information for the study 
and were encouraged to contact the researchers to arrange a day and time to be interviewed. Such interviews 
were conducted at the interviewee’s home or another suitably private site. All consenting participants were 
interviewed. Inclusion criteria were as follows:  
(i) Primary caregiver of at least one HIV-positive child (age 0-14);  
(ii) Caregiver acknowledges that child has been informed of his or her HIV status. The interviewer 
were not required to restrict their responses to only this child if they cared for multiple children; 
and 
(iii) At least one child is receiving antiretroviral therapy or prophylactic antibiotic therapy.  
The second criteria served two purposes: it ensured that participating caregivers had experienced the 




they had with children who may not know their status. Written informed consent was obtained in English, 
Runyankole, or Luganda as appropriate.  
In situations where the participant’s literacy level prevented written informed consent from being obtained, 
an equivalent verbal consent agreement was made available. The Ethics committees at both institutions as 
well as the Uganda National Council for Science and Technology approved these consent procedures. The 
reading of the form was recorded, and interviewees providing consent were asked to verbally assent to 
continuing the interview as well as indicating on the consent sheet using either a signature or thumbprint. 
Participants were informed that their involvement was entirely voluntary and that they may choose to not 
answer questions if uncomfortable, and may stop the interview at any time.  
3.3 Use of Translators 
A translator fluent in English, Runyankole, and Luganda and specifically trained to assist in administering 
the interview questionnaire was present for interviews where the volunteer was unable to conduct the 
interview in its entirely in English. Using mock interviews, translators were trained to ensure complete 
fidelity to what was actually said by the interviewer and interviewees without paraphrasing or 
embellishment, consistency between interviews, and signed a confidentiality agreement prior to assisting 
in the study. All interviews were transcribed by a second translator, who was instructed to look for any 
discrepancies between what was said by interviewees and what was reported by the primary translator 
(where applicable). 
3.4 Interview Content 
The interview questionnaire was designed with assumptions of naturalistic inquiry in mind, particularly 
Phenomenology – the belief that the object of interest should be examined without any preconceived notions 
or expectations – and Presupposition-less research – that the researcher does not assume that his or her 
norms, values or ideology are shared with the interview subjects. To this end, interviews consisted primarily 
of open-ended questions that encouraged the caregiver to build a narrative of their experiences informing 
the child of their HIV positive status. Questions focused on the caregiver’s experiences and attitudes 
regarding the experiences of HIV status testing and the disclosure of the status to the child. Closed-ended 
questions that aimed to collect numeric and categorical data, such as age of disclosure, were also included. 
All closed-ended questions were followed up with open-ended questions where caregivers were encouraged 
to describe in their own words the reasoning and context of behind their responses.  Interviews were semi-
structured and took 45-75 minutes to complete. 




Text files of all interview transcripts were imported into HyperResearch 3.5.2. Responses to open-ended 
questions were used, both individually and collectively, to generate word counts. Frequently used words 
were examined for context and used to generate the code book. These codes were then applied to transcripts 
in order to identify recurring themes in the responses.  
 
 
Chapter 4: Results 
4.1 Characteristics of Caregivers and Children 
A total of 28 caregivers were interviewed (Table 4.1.1), of these 21 were the biological parent of the child 
and 19 of whom self-identified as being HIV positive. Disclosure experiences of 31 children were discussed 
during the course of the study. 
Table 4.1.1: Characteristics of Caregivers and Children 
Characteristic Frequency %a Characteristic Frequency %a 
Age of Caregiver (Years)  Occupation of Caregiver  
19 2 7 Owns business 4 14 
21-30 5 18 Labourer 6 21 
31-40 12 43 Farmer 10 34 
41-50 7 25 Hawker 2 4 
51-60 1 4 Mechanic 1 3 
60+ 1 4 Hairdresser 1 3 
Caregivers  Tailor 1 3 
Male 5 18 Works in shop 1 3 
Female 23 82 Cook 1 3 
Marital Status of Caregiver  None 2 7 
Married 12 43 Place of Dwelling    
Divorced 7 25 Urban 2 7 
Widowed 5 18 Small town 4 14 
Never married 4 14 Village 22 79 
HIV Status of Caregiver  People in Household  
Positive 21 75 2 – 4 7 25 
Negative 5 18 5 – 7 17 61 
Not tested 1 4 8 + 4 14 
Declined to say 1 4 Child's Age (years)  
Relationship to Child  0 – 5 3 10 
Biological parent 21 68 6 – 10 14 45 
Step parent 5 16 11 – 14 14 45 
 13 
Grandparent 1 3 Child's Age at Diagnosis (years) 
Aunt/Uncle 1 3 0 – 5 22 71 
Great Aunt/Uncle 1 3 6 – 10 9 29 
Brother 1 3 11 – 14 0 0 
Teacher 1 3 
Children Experiencing 
Partial Disclosure 
Before Full Disclosure 
13 42 
a Percentages may not total 100% due to rounding 
4.2 Challenges Reported by Caregivers of HIV Positive Children 
When participants were asked to describe in their own words the challenges they face as caregivers of HIV 
positive children, several themes were identified by the frequency of specific words that were used in the 
responses (Fig. 1). Caregivers most commonly mentioned difficulty in affording transportation, which was 
described as being a barrier to keeping appointments at the hospital. Difficulty in affording nutritious food 
for the child was another common challenge reported by caregivers. Finally, many caregivers reported 
difficulty in caring for the positive child when the child had fallen ill. 
Challenges directly related to the child’s HIV-related medications were also mentioned in the caregivers’ 
responses, but much less frequently than those dealing with transport, food security and illness. Such 
challenges included with the child’s medication adherence, lapses in medication availability, and concerns 
over the side effects of the child’s medication.  
4.3 Attitudes and Behaviours Related to HIV Testing 
Although difficulty affording transportation was the most common challenge reported by the caregivers 
(Fig. 1), this did not appear to be a significant roadblock to HIV testing or counselling; a majority of all 
caregivers interviewed considered it relatively easy to access HIV testing and counselling services in their 
community.  Of caregivers who were themselves tested for HIV, a majority chose to do so in response to 
existing illness either in themselves, their spouse, or the child under their care (Table 4.3.1). Similarly, the 
reasons cited by caregivers for getting the child tested for HIV were overwhelmingly related to the child, 
the parent, or another family member exhibiting signs of illness (Table 4.3.2) with vast majority of children 
being tested as a response to symptoms of illness in themselves or others. The age at which children were 
tested for HIV varied greatly (Table 4) and no children were reported to have been tested as part of standard 
postnatal care (Table 4.3.2). Among interviewed caregivers, most reported having the child tested for HIV 





Figure 4.3.1: Word Cloud of Responses to "Describe the challenges you face as the caregiver of an HIV-positive child." 
 
Table 4.3.1: Reason for testing self for HIV. 
Reason Frequencya %b 
Encouraged by community leaders to get tested 1 3 
Tested as part of antenatal care 3 10 
Child was sick/weak 2 7 
Spouse got sick or died 5 17 
Felt sick/weak 10 34 
Just wanted to know HIV status 5 17 
Child tested positive for HIV 2 7 
Wanted to know if sexual partner was HIV positive 1 3 
a Frequency may not total n=28 due to responses in multiple categories 
b Percentages may not total 100% due to rounding 
 
 














Child was sick/weak 23 74 
Parent was sick or died 6 19 
Sibling was sick/weak 1 3 
Parent was known to be positive 3 10 
Recommended by health care worker 1 3 
Caregiver wanted to know status of child's father 1 3 
Tested as part of standard postnatal care 0 0 
a May not total n=31 due to responses in multiple categories 
b Percentages may not total 100% due to rounding 
 
Table 4.3.3: Age in Years of Key Events in Disclosure Process. 
        
 
Event 





 HIV Testing     4 3 
 Initiation of HIV Education/Information Process    7 2 
 Partial Disclosure of HIV Status   6 2 
 Full Disclosure of HIV Status    7 2 
 Interval Between Testing and Disclosure   3 3 
 
Interval Between Initiation of HIV Information and Disclosure  




        2 
 
Table 4.3.4: Person Most Responsible for Providing HIV Information 
   
Relationship Frequency Percent 
Caregiver Alone 25 84% 
Counsellor Alone 1 3% 
Caregiver and Counsellor 
Together 3 10% 
Other Relative 1 3% 
 




The data showed that the process to begin informing on HIV was initiated at a mean age of 7 years old 
(Table 4.3.3). When the HIV information process was described by the caregivers, the caregivers identified 
themselves as being most responsible for informing the child about HIV, either by themselves or in concert 
with an HIV counsellor, in nearly all cases (Table 4.3.4). When asked to describe the process by which the 
children were informed about HIV, the caregivers’ responses revealed several themes. First, many 
caregivers expressed doubt that the child understood what they were being told, especially when the child 




A lack of reaction on the part of the child was another sign caregivers interpreted to mean when explaining 
their feelings that the child did not understand (Text box 4.4.1). Other caregivers reported that the child felt, 
or might feel that their diagnosis was a death sentence, with 68% believing that a child would feel that their 
life was without hope if they knew their status (Text Box 4.4.2, Fig. 4.4.2). 
Text Box 4.4.1: Selected responses illustrating emerging theme of doubts that the child truly 
understood when informed of their HIV status. 
“The first time [we disclosed] I wasn’t sure if she understood. Now I know she knows.” (Biological 
mother, 38 years old, HIV positive, Status disclosed at age 5). 
“She asks me every time, like every two months she will ask me why she has to swallow the 
medicines.” (Biological mother, 29 years old, HIV positive, Status disclosed at age 7). 
“He didn’t react [when told]. I didn’t notice a change, as if he didn’t understand.” (Biological father, 44 
years old, HIV positive, Status disclosed at age 5). 
“He didn’t react [when told] … He is too young to know.” (Biological mother, 50 years old, HIV 






















4.5 Attitudes and Behaviours Related to Disclosure of HIV Status 
Following initial open-ended questions, caregivers were read a brief section of statements and asked 
whether they felt the statements were mostly true or mostly false (Fig. 4.4.2). The purpose of this section 
was to act as a comparison to open-ended responses recorded earlier in the interview as well as to prompt 
additional open-ended questions. 
Text Box 4.4.2. Selected responses given when asked to expand on True/False answer to statement: 
“An HIV-positive child will feel that their life is without hope if informed of their HIV status” 
Caregivers who said “True” (68%): 
 “Because after her elder [10 year old] sister had learned that [her younger sister] was HIV positive, 
she told the grandmother that she should poison [her] so she could die, because there is no future.” 
(Biological mother, 29 years old, HIV positive, Status disclosed at age 7). 
“From the moment you tell the child they have AIDS, I think they will lose hope, because you will 
think you will die any time. Later on, they may understand that the ARVs [antiretroviral medications] 
will help them live longer.” (Brother, 19 years old, HIV status unknown, Status disclosed at age 8). 
“One child I knew refused to swallow his ARVs because he felt he didn’t have a future.” 
(Biological mother, 30 years old, HIV positive, Status disclosed at age 6). 
“True, because they don’t really know what AIDS is. They don’t know that with ARVs they can still 
live longer.” (Uncle, 56 years old, HIV negative, Status disclosed at age 7). 
“True, because they think that at any time they are going to die.” (Biological mother, 38 years old, 
HIV positive, Status disclosed at age 5).  
Caregivers who said “False” (32%): 
“Because if they informed him or talked to him more about HIV he won’t feel that way.” 
(Biological father, 45 years old, HIV negative, Status disclosed at age 6). 
“If you tell the truth, and tell her that she will live longer with medication she won’t lose hope.” 
(Biological mother, 36 years old, HIV positive, Status disclosed at age 6). 
“…if you tell them when they are young they will think that HIV is normal, since they are growing 
up like [other children].” (Biological mother, 36 years old, HIV positive, Status disclosed at age 6). 
“If the child thinks that they can be cured, they won’t lose hope.” (Stepmother, 24 years old, HIV 




Many attitudes and expectations related to HIV disclosure were shared by the caregivers interviewed. All 
caregivers felt that a child who knows his or her HIV status will have a “Good attitude towards his or her 
medications”. However, a significant majority of caregivers relayed that a child with HIV would blame 
their parents for their HIV infection if their status were disclosed (Text Box 4.5.1), and many reported that 





Text Box 4.5.1. Selected responses given when asked to expand on True/False answer to 
statement: “An HIV-positive child will blame their parents for their HIV infection if they are 
told.” 
Caregivers who said “True” (84%): 
“…those who got the AIDS from their parents will blame them because they are the ones who 
infected them.” (Biological parent, 30 years old, HIV positive, Status disclosed at age 5). 
“Because they feel that they are innocent, and if the mother didn’t have AIDS they would be free.” 
(Biological mother, 40 years old, HIV positive, Status disclosed at age 7). 
“I think the child would think that, if my mom didn’t have AIDS, [the child] would be free.” 
(Biological mother, 36 years old, HIV positive, Status disclosed at age 7). 
 
“They would blame the parents because the child is innocent, and it’s the parents who gave them 
the disease.” (Uncle, 56 years old, HIV negative, Status disclosed at age 7). 
Caregivers who said “False” (16%): 
“False, because if they have taught him and shown him how HIV is spread, they won’t blame it on 





Text Box 4.5.2. Selected responses given when asked to expand on True/False answer to 
statement: “An HIV-positive child will be discriminated against in your community if the 
community learns of the child’s HIV status.” 
Caregivers who said “True” (79%): 
“…the majority are not informed about AIDS. They tend to think that, if [the child] goes with 
them, he will spread the disease.” (Biological father, 45 years old, HIV negative, Status 
disclosed at age 6). 
“They may have misconceptions, like that AIDS is spread through sharing food. They may not 
want the children to play together.” (Biological mother, 36 years old, HIV positive, Status 
disclosed at age 7). 
“Our relatives and community members were telling her that she was already dead, that she has 
no use.” (Biological mother, 38 years old, HIV positive, Status disclosed at age 5). 
“True, because I see her cousins pinpoint her and refuse to eat with her.” (Biological mother, 
29 years old, HIV positive, Status disclosed at age 7). 
“When they know you are positive, they tend to push you away, children especially.” 
(Grandfather, 73 years old, HIV negative, Status disclosed at age 8). 
 “Yes. Some people tend to think that, when the child eats food with other children who are 
HIV negative, they think the HIV would spread. Or, when they play games, [the child] could 
hurt themselves and spread HIV.” (Biological mother, 40 years old, HIV positive, Status 
disclosed at age 7). 
“True, because they think that they will spread the HIV to others.” (Biological mother, 38 
years old, HIV positive, Status disclosed at age 11). 
“They think the child will spread the sickness to their children.” (Brother, 19 years old, HIV 
status unknown, Status disclosed at age 8). 
“Because they will think they will spread the disease to the children who are negative.” 
(Biological mother, 39 years old, HIV positive, Status disclosed at age 9). 
Caregivers who said “False” (21%): 
“False, because at the time many people are infected with HIV.” (Biological mother, 30 years 
old, HIV positive, Status disclosed at age 5). 
“…people know how HIV is [sic] and they will take it as normal.” (Biological mother, 43 




Nearly half (42%) of caregivers admitted to initially telling the child that they were sick with a disease other 
than HIV (Table 4.1.1), with malaria being the most common disease mentioned in this way. This partial 
disclosure occurred at a mean age of 6 years (Table 4.3.3). When prompted to discuss their motivations for 
deceiving the child, a theme of feeling that the child was too young or otherwise unable to understand 
emerged (Text box 4.4.1).  Among other caregivers who chose to partially disclose the illness to the child, 
many expressed fears about how the child will react to the knowledge. 
Full disclosure of HIV status, when it occurs, typically happens at age 7 (Table 4.3.3). Similar to the pattern 
observed with respect to who is most responsible for providing the child information on HIV, the caregiver 
interviewed identified themselves as the person who disclosed the status to the child in the vast majority of 
cases (Table 4.5.1).  The amount of time between when the child first began to be informed about HIV and 
the initial disclosure event was less than a year in the vast majority of cases (Table 4.3.3). 
When asked to describe the process by which caregivers prepared themselves and the child prior to the 
initial disclosure event, two main yet contrasting themes were evident. Responses commonly described 
seeking out an HIV counsellor or health care professional for advice on what they should say or do when 
they disclosed the status. When pressed for additional details as to the type of instruction these information 
sources provided, caregivers were unable to provide specifics. The other theme common to many responses 
was a lack of preparation of any kind before initiating disclosure. In either case, the decision to disclose 
was made in response to the child asking questions about his or her medication or refusing to either take 
the medication or attend regular clinic appointments (Text Box 4.5.3). 
  
Table 4.5.1 Person who disclosed HIV status to child. 
Person Frequency % 
Caregiver 23 82 
   
Other relative 2 7 
Doctor 2 7 


















When asked to describe what they said during the initial disclosure event, HIV positive caregivers 
commonly reported disclosing their own HIV status to the child at the same time they disclosed the child’s. 
Similarly, caregivers who were not the biological parent of the child commonly reported informing the 
child that his or her parent was also HIV positive as part of the initial disclosure event. Caregivers also 
described stressing to the child that taking their HIV-related medications was crucial to their health and 
future, although many also reported telling the children that their antiretroviral medications would 
eventually cure them of the disease (Text Box 4.5.4). 
 
Text Box 4.5.3. Selected responses to question: “What made you decide to tell the child 
that he or she had HIV?” 
Caregivers who mentioned medication adherence as main or sole reason: 
“Because she asked why she was taking her medicine.” (Biological mother, 30 years old, HIV 
positive, Status disclosed at age 5). 
“I wanted him to not refuse to take his medicine.” (Biological mother, 36 years old, HIV 
positive, Status disclosed at age 6) 
 “I was asked why she was swallowing the medicine, and I told her the truth.” (Biological 
mother, 36 years old, HIV positive, Status disclosed at age 7). 
“[she] had been refusing medicines, and the hospital advised us to tell the child” (Grandfather, 
73 years old, HIV negative, Status disclosed at age 8). 
“We wanted him to know so he would take his medicines well and on time” (Biological father, 
44 years old, HIV positive, Status disclosed at age 5). 
“She was asking why she had to swallow the medicine.” (Biological mother, 36 years old, HIV 
positive, Status disclosed at age 6). 
“I saw that she was mature, and she was asking why she was taking the medicines.” (Biological 





 Text Box 4.5.4. Selected responses to question: “Please tell me, in your own words, what you said 
[when you disclosed the status to the child]?” 
“I told her that I was sick, and that when I gave birth to you, you were sick. But don’t worry, we will 
both swallow the medicine and we will be fine. It will make us both good. In time, we won’t need to 
swallow the medicine because we will be healed.” (Biological mother, 39 years old, HIV positive, 
Status disclosed at age 9). 
“He [the doctor] told him that he was tested and found HIV positive, but that I am going to give you 
this medicine to take and with time you’ll be okay.” (Stepmother, 24 years old, HIV positive, Status 
disclosed at age 5). 
“I told him, if you don’t swallow the medicine, you are going to become very sick like the way you 
were before. Also, I told him that he got AIDS when I was giving birth to him.” (Biological mother, 
36 years old, HIV positive, Status disclosed at age 6). 
“I told him that the father spread the HIV to me and he was born with HIV. I also warned him that he 
needs to take his medicine regularly.” (Biological mother, 30 years old, HIV positive, Status disclosed 
at age 6). 
“I told her to fear AIDS and I told her how it is spread. Then I told her that she got it from us, the 
parents. Finally, that she should take the drugs and never spread it to others.” (Biological mother, 38 
years old, HIV positive, Status disclosed at age 10). 
“I told him that you are HIV positive and you are to be on this medication for the rest of your life.” 
Biological mother, 43 years old, HIV positive, Status disclosed at age 13). 
 “I explained to her that she and I were both sick, and that she should learn to love herself the way she 
is. Also left her under the care of her godmother if I wasn’t there anymore.” (Biological mother, 36 
years old, HIV positive, Status disclosed at age 7). 
“When she was leaving for boarding school, I sat her down and told her to take her medicine. I also 
told her to not share any sharp instruments with your friends because you could spread HIV. She 
asked me, ‘I have HIV?’ and I said ‘Yes, you got it when I was producing you”. (Biological mother, 
38 years old, HIV positive, Status disclosed at age 5). 
“I told her that your father recently passed away. He died of AIDS. Also, you are born with AIDS. 
You need to take your medicine, it will help you to live longer.” (Biological mother, 29 years old, HIV 
positive, Status disclosed at age 7). 
“[when leaving hospital] I asked him ‘Do you know where we are coming from, and what we were 
doing there?’ He said no. I told him, ‘You are there to collect this medicine. This medicine is for HIV, 
and you are HIV positive. And the HIV, you got it from your parents.” (Uncle, 56 years old, HIV 
negative, Status disclosed at age 7). 
“We told him that he had HIV, that he got it from both his parents from birth when his mother was 
producing him. We told him about what his medicines do, how the ARVs help him.” (Biological 




4.6 Perceived Effects of HIV Status Disclosure 
Of those caregivers who described the experience of disclosing HIV status to an HIV-positive child under 
their care, 80% believed that the way in which they did so was a “good idea” and that disclosing the status 
to the child resulted in positive outcomes (Text Box 4.6.1). However, an important theme emerged 
following disclosure was the doubt expressed by the caregiver whether the child understood what they were 
being told. This theme recurred in the accounts of multiple caregivers and across the full range of ages of 






4.7 Triangulation of Results Within Methodology 
Caregiver responses tended to remain consistent throughout individual interviews. However, three notable 
exceptions are described below. 
When asked to tell the interviewer a story about a time when the child under their care missed a dose of 
ARVs or antibiotics, 39% said the child never missed a single dose. Within this subgroup, however, 
Text Box 4.6.1. Selected responses to the question: “Do you think that telling the child when you 
did and how you did was the right decision?” 
Caregivers who said “Yes” (80%): 
“At that age, the child was ready and could understand what it meant [to have HIV].” 
(Biological mother, Age 30, HIV positive, Status disclosed at age 5) 
 
“I wanted her to know in case I die that she has AIDS, and so she wouldn’t learn it from other 
people.” (Biological mother, Age 40, HIV positive, Status disclosed at age 7) 
“If I didn’t tell him, he would still be refusing to swallow his medicine.” (Stepmother, Age 24, 
HIV positive, Status disclosed at age 3). 
“Yes, he is determined to swallow his medicine.” (Stepmother, Age 24, HIV positive, Status 
disclosed at age 5). 
“I wanted him to know, so he wouldn’t be asking so many questions about why he was 
swallowing the medicine.” (Biological mother, Age 36, HIV positive, Status disclosed at age 
6). 
“I wanted her to be comfortable with her life, not compare herself to everyone who doesn’t 
have it, and also not to blame me because she got AIDS through me.” (Biological mother, Age 
36, HIV positive, Status disclosed at age 7). 
 
Caregivers who said “No” (20%): 
“She wanted to hang herself. She went down to this river nearby to drown herself. We stopped 
her on the way there… I took her to the hospital to close her in a room for a week so she 
wouldn’t hurt herself.” (Stepmother, Age 38, HIV positive, Status disclosed at age 9). 
“The child started hating herself after I told her she had AIDS. Also, at that age I don’t think 
she was ready to hear it.” (Biological mother, Age 29, HIV positive, Status disclosed at age 5). 
“No, because the child wasn’t old enough at the time … I should have told him at around 7 




responses to open-ended questions revealed an emergent theme of difficulties in medication compliance 
Medication compliance was reported to either be improved following HIV status disclosure, or as a result 
of the child being informed of their HIV status because they were refusing to take their medication. This 
inconsistency may suggest that a proportion of caregivers may be reluctant to openly admit instances of 
medication noncompliance, a phenomenon that has been previously observed in multiple studies (10, 30). 
Alternatively, the apparent discrepancy between results could reflect that children were reluctant to take 
medications pre-disclosure, and that this reluctance was diminished following disclosure. 
 
Another discrepancy occurred between caregiver response to the statements “An HIV-positive child will 
feel that their life is without hope if informed of their HIV status” and “An HIV positive child will feel that 
their future is limited if informed of their HIV status.” (Fig. 4.2)  While 68% responded true to the first 
statement and 44% responded true to the second statement, only 68% of these caregivers responded to both 
statements in the same way. Upon further discussion, it became clear that the caregivers were interpreting 
the term “future” to refer to the child’s prospects of obtaining an education or employment. 
 
Finally, caregivers’ general attitudes toward disclosure were surprisingly negative, with caregivers agreeing 
that children who learn their positive status may be discriminated against in their community, feel their life 
is without hope, or blame their biological parents for their infection (Fig. 4.2).  These attitudes were present 
among caregivers despite 80% of them believing that disclosing HIV diagnosis to children under their care 
was the right decision (Text box 4.6.1). This may be due to the caregivers observing the negative outcomes 
experienced by other members of their community during their own disclosure experiences, a rationale that 












Chapter 5: Discussion 
5.1 Disclosure Experience of Interviewees vs. Current Guidelines 
When looking at the disclosure experiences of caregivers from start to finish, several key differences from 
current guidelines become apparent. Current recommendations for disclosing a child’s HIV status include 
the formation of a disclosure plan between the caregiver and an HIV counsellor that takes into account the 
family’s dynamics, the child’s intellectual development, and the goals of the caregiver. Once the plan is in 
place, the child should be informed about the disease in a developmentally appropriate manner prior to the 
initial disclosure event. Once informed of their HIV status, guidelines suggest that the child and caregiver 
continue to discuss the child’s HIV status and its impact on their life in growing complexity as the child 
matures intellectually (New York State Department of Health AIDS Institute 2009, WHO 2011). However, 
the caregivers’ responses indicated that more than a third (36%) of the respondents embarked on disclosing 
the status to the child without first seeking help.  Many more caregivers expressed doubts that the child had 
indeed understood what they were being told. This is supported by recent research involving caregivers of 
HIV-positive children in Mbarara, Uganda as well as in the Democratic Republic of Congo, both of which 
suggest that caregivers tend to view HIV status disclosure as a single step as opposed to an ongoing process 
(Kiwanuka et al. 2014, Vaz et al. 2010). This lack of involvement on the part of health care workers and 
HIV counsellors in the pre-disclosure preparation may lead to sub-optimal or harmful disclosure 
experiences.  
The narratives provided by the caregivers looked at who they sought out for advice regarding disclosing 
the HIV status to the child and what they did to prepare themselves and the child before the initial event. 
None of these narratives touched upon whether these choices were made against the advice of their health 
care providers. Further, when caregivers were able to describe the nature of advice provided to them by 
HIV counsellors or other health care workers, none of these descriptions included expected points such as 
approaching disclosure in a stepwise manner, the formation of a disclosure plan, or the counsellor acting as 
a facilitator for the HIV information and disclosure process.  
5.2 Who Discloses Status 
In nearly all cases, it was the caregiver or another relative who disclosed the HIV diagnosis to the child. 
Only rarely, in 11% of cases (Table 4.3.4), was the HIV status initially disclosed by a health care worker 
such as a physician or HIV counsellor. This is in line with data from multiple other studies conducted 
throughout Sub-Saharan Africa (Atwiine et al. 2014, Vaz et al. 2010). Current recommendations do not 




care professional, so long as that person is selected while being mindful of the effect of HIV status 
disclosure on the child’s well-being (Cantrell et al. 2013, WHO 2011). 
5.3 Education of Child Regarding HIV 
The data collected here suggest that, regardless of the age of disclosure, provision of HIV information tends 
to begin immediately prior. Thus, children with little or no HIV knowledge may be inundated with 
information in a relatively short period of time, culminating in the disclosure of their HIV status. This 
occurred over a wide range of intervals (Mean = 3 years, SD = 3 years) between the child testing positive 
and the initial disclosure event (Table 4.3.3). Learning their HIV status in this manner, as opposed to a more 
stepwise approach that tailors the information given to the child’s intellectual development, may lessen the 
positive effects of disclosure.  
 
5.4 Partial Disclosure 
The rate of partial disclosure reported by interviewees revealed that nearly half of all positive children were 
first only told that they were sick, or were told that they had a disease other than HIV. Further, among 
children who experienced partial disclosure prior to full disclosure, this deception would typically last for 
several years. This practice reflects the caregivers’ reported doubts that the children were capable of 
understanding full disclosure of their HIV status, but the duration of partial disclosure may also suggest a 
reluctance to fully disclose that was not explicitly addressed in the interview responses. In either case, the 
frequency and duration of partial disclosure represent an aspect of the disclosure experience that may be a 
target for future interventions.      
 
5.5 Results of Disclosure 
Across the entire range of disclosure ages, there was a persistent theme of caregivers doubting that the 
children fully understood the information shared at the time of disclosure. This may be due to baseline 
differences in the quality or extent of instruction the child and caregiver received prior to beginning the 
disclosure process, something that was not controlled for in this study. Another possible explanation is that 
the malnutrition common in HIV positive children may result in delays in cognitive development. To date, 
the existence of a link between malnutrition and poor HIV disclosure outcomes has not been investigated 
and thus provides the opportunity for future study. If a link were found it could mean that, for this patient 
population, the optimal ages to begin the HIV education process and disclosure process may differ from 




Many caregivers responded in the affirmative to the statement that a child would feel that their life is without 
hope if they learned of their status (Fig. 4.2). The reported reactions of some of the children who learned 
their status, which ranged from confusion to stoic acceptance to self-harm or attempted suicide, lends 
credence to this. As access to counselling does not appear to be a significant roadblock, educating caregivers 
and counsellors in the steps to take prior to disclosure (e.g., planning how to disclose with a counsellor and 
ensuring that the child has a baseline knowledge of HIV including the knowledge that the disease should 
not be considered an automatic death sentence) may be pertinent steps to change the disclosure experiences 
of Ugandan families that may result in more positive outcomes for at-risk children. A longer-term study, 
where positive children are followed through the disclosure process and beyond, would be the logical next 
step to identify potential benefits of a more formalized disclosure process that stresses education of 
caregiver and child. Identifying the baseline instruction health care providers in the area receive regarding 
HIV disclosure to pediatric patients would be a key first step to completing such a study. Further, assessing 
the children’s HIV knowledge directly throughout the education and disclosure process would provide more 
robust data on the child’s true disclosure experience. 
5.6 Caregivers’ Attitudes Regarding HIV Status Disclosure 
Caregivers’ attitudes towards HIV status disclosure were frequently negative, with the overwhelming 
majority believing that the child would feel that their life was without hope when they learned their status, 
that they will blame their parents for their HIV infection if told, and/or that they would accidentally disclose 
his or her status to the community (Fig. 4.2). Interestingly, even caregivers who reported a positive 
disclosure experience shared the beliefs that disclosure would have negative consequences. Despite these 
admissions, all (100%) of caregivers believed that disclosure would result in the child having a better 
attitude toward their medications.  
In spite of efforts to promote HIV testing as part of routine medical care, the vast majority of HIV tests 
discussed in the interviews were motivated by active symptoms – either in a child, parent, sibling, spouse, 
or the individual themselves. The fact that nearly every respondent viewed HIV testing and counselling 
services as easy to obtain in their community suggests that more education and outreach may be necessary 
to convince at-risk individuals in rural Uganda to get tested for HIV before they fall ill. Such efforts would 
also serve to address the fact that the vast majority of interviewees report that, in their communities, HIV-







The study suffers from several limitations. Although the sample size of 28 caregivers discussing the 
experiences of 31 children is more modest than some contemporary studies examining HIV status 
disclosure in Sub-Saharan Africa, this is largely due to the decision to restrict participation in the study to 
caregivers who had fully disclosed the HIV diagnosis to the child under their care. As recent evidence in 
the area suggests (Atwiine et al. 2014), this decision would exclude 69% of caregivers presenting at the ISS 
clinic. Further, the sample size used is significantly larger than many relevant qualitative studies recently 
released (Chi-Ling and Rosemary 1999, Vaz et al. 2010). 
Similarly, as the study design selected for caregivers who lived in a specific region of Uganda, attended a 
specific ISS clinic, had disclosed the HIV status to at least one child under their care, and who was caring 
for at least one child who was receiving ARV therapy or antibiotic prophylaxis, the experiences of these 
caregivers may not be representative of the majority of caregivers of HIV positive children in Southwestern 
Uganda, let alone Sub-Saharan Africa. Although the experiences of caregivers in this study were similar to 
those reported in other studies (Atwiine 2014, Kiwanuka et al. 2014), it would still be premature to declare 
these experiences to be the norm. 
As little was known about the disclosure experiences of the caregivers of HIV-positive children when this 
study was being designed, questions were approached using the assumptions found in Naturalistic Inquiry 
in order to avoid inadvertently projecting the researcher’s preconceptions and biases on the results. 
Although this decision allowed interviewees to build their own narratives about their experiences with HIV 
testing and disclosure, the approach meant that the data collected could not be subjected to the same 
statistical analysis that the data obtained from a more closed-ended survey. Future studies can draw upon 
the results of this study to generate a more focused questionnaire without fear that issues important to the 
caregivers are being marginalized. 
Another potential limitation involves the challenge inherent in conducting semi-structured interviews via 
interpreters. Although all translators employed in the study were extensively trained and urged to strive for 
consistency between all interviews, using mock interviews to identify and address potential issues before 
they were encountered, some caregivers clearly interpreted certain questions differently than others. To 
avoid steering interviewee responses to the researchers’ preconceptions or putting words in the subjects’ 
mouths, the interviewees were simply requested to clarify their position before responses were coded ‘as 
is’. By using a second translator to validate the first translation, we feel that all questions and answers are 




The original study design was going to compare the responses of caregivers recruited at the ISS clinic with 
those recruited through FAOC. As we began to collect data, however, we noticed that there was significant 
overlap between the two groups. For one thing, caregivers recruited via FAOC were often receiving their 
treatment in Mbarara and caregivers recruited at the ISS clinic often were living in the rural parishes 
surrounding Mbarara. Thus, the rural vs. municipal comparison was not possible, as the two methods of 
sampling were drawing participants from the same populations. 
The recruitment process was designed so that neither the interviewers, health care workers, nor FAOC 
chairpersons would be able to influence who would be invited to participate. Hence that decision to pool 
the data from the two sampling methods would not introduce bias. In the ISS clinic, all caregivers presenting 
were screened and, if found to be eligible, all were invited to participate. At FAOC meetings, all members 
were informed of the study at meetings and were encouraged to contact us if they felt that they met the 
criteria and were interested in participating. The only potential difference in the two groups would be that 
the caregivers approached directly at the ISS clinic would be more likely to participate than those who were 
simply made aware of the study at FAOC meetings and had to take the additional step of contacting us to 
volunteer. We noticed greater numbers of participants volunteering through the ISS clinic vs. the FAOC 
meetings and thus directly comparing the two groups may not necessarily be valid. The level of education 
of the caregiver and their detailed knowledge about HIV AIDS was not specifically addressed and may 
have been different between the ISS clinic and the FAOC groups, but the mixing of the groups would 
mitigate any effect. The ethical challenges inherent in interviewing HIV positive children with potentially 
different levels of awareness of their HIV status prevented the researchers from directly assessing each 
child’s level of HIV knowledge. It would be unacceptable, for example, for an interviewer to accidentally 
disclose the child’s HIV status to him or her if the caregiver was somehow misinformed as to the child’s 
knowledge of their own HIV status. For these reasons, the study was less concerned with the exact 
knowledge possessed by the children as opposed to understanding when the process of informing began for 
each child with respect to HIV, and how this fit into the disclosure process. The downside to this focus is 
that the study is dependent on caregivers being able to accurately assess the extent to which a child 
understood when they were informed of their HIV status. For this reason, it is possible that the number of 
children who do not fully understand the realities of their HIV infection following disclosure differs from 
what caregivers reported. Directly assessing the HIV knowledge of the children involved and how that 
knowledge changes throughout a stepwise disclosure process will be a crucial component of future research 
into this topic. 
Interview format is, historically, an unreliable way to accurately assess medication adherence, as it 




(Miller and Hays 2000, Wagner and Rabkin 2000). For this reason, the study does not investigate potential 
relationships between a child’s disclosure experience and their drug compliance. Ultimately, determining 
any effect of disclosure method on drug compliance will be important, especially once the child in question 
reaches an age where they take responsibility for administering their own medications. In such a scenario, 
review of medication refill timings and trends in CD4 counts will likely produce the most accurate picture 
of overall medication compliance.  
Finally, many of the questions depend on the recall of the caregiver. As such, the narrative built by each 
interview to describe the disclosure process and results is subject to the limitations of the caregiver’s 
memory. To combat this, the questionnaire was designed to avoid influencing what aspects of HIV testing, 
education, and disclosure the caregiver chose to focus on, instead encouraging the caregivers to speak about 



















Chapter 6: Conclusion 
Overall, disclosure experiences reported by caregivers may be resulting in sub-optimal outcomes. HIV 
testing of children was almost always initiated due to symptoms of illness in either the child or a relative. 
Informing the child that they had a disease other than HIV was common, and this partial disclosure tended 
to last several years before full disclosure was attempted. Over one third of all caregivers reported not 
preparing at all before attempting to disclose the status to the child, and only two caregivers described 
ensuring that the child had an understanding of what it meant to have HIV before attempting disclosure. As 
a potential result of these characteristics of the disclosure experience, many caregivers described informing 
the children of their diagnosis before the child was able to fully understand the disclosure, and this 
disclosure appeared to be a discrete event, as opposed to an ongoing process, in nearly all cases. As access 
to HIV counselling was not deemed to be a roadblock by all but a few caregivers, changing disclosure 
practices may be as simple as providing more concrete guidelines for HIV counsellors to follow to ensure 
that positive children are adequately informed about HIV prior to disclosure once there is evidence of the 
child having entered the Concrete Operational phase. Whether such changes will result in measurably better 
















Chapter 7: Future Directions 
An inability to consistently assess the nutritional status of children from birth through to the date of the 
interview meant that the question of whether malnutrition affects the optimal age of disclosure remains 
unaddressed in this paper. Although not presented in the results section of this paper as direct observation 
of the children was not part of the study design, interviewers did observe visibly stunted children on 
occasion before or after conducting the interview with the caregiver. A more thorough investigation of this 
characteristic of HIV positive children in this setting seems absolutely warranted.  
Knowing that HIV status disclosure to children in Uganda tends to occur at school age, be treated as a single 
discrete event as opposed to an ongoing process, and occur without advice from a health care provider or 
HIV counsellor, the opportunity exists to augment the disclosure process children experience and identify 
how these interventions alter the outcomes of disclosure. Standardizing the training of local HIV 
counsellors would be a logical next step. Specifically, staff would be encouraged to discuss the concept of 
disclosure with caregivers while the child is still in early childhood, promote the education of the child 
regarding concepts of illness prior to school age, and working with the caregiver to identify their concerns 
and priorities in order to develop a disclosure plan tailored for each child. This plan would encompass HIV 
education for both caregiver and child, helping the caregiver identify and overcome potential barriers to 
disclosure, and includes follow-up discussions with both the caregiver and HIV counsellors at subsequent 
clinic visits. The success of this manner of disclosure could be measured in many different ways. As a more 
thorough disclosure process would be hypothesized to result in improved coping skills and socialization for 
the child, caregivers could be interviewed in a manner similar to what was used in this paper. Effects on 
ARV medication adherence could be assessed as the child matures and assumes greater responsibility for 
his or her health, with the expectation that a more successful disclosure experience would result in increased 
rates of adherence. Ultimately, how a child learned of his or her positive diagnosis could also impact their 
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Appendix A: Interview Questionnaire and Informed Consent Forms 
Research Topic:  Assessment of caretakers’ attitudes towards HIV 
testing and disclosure of HIV status to at- risk children in rural 
Uganda    
 Participant Number:   
Place of Interview:  (Tick) 
 Date of Interview:  
DD                      MM YYYY 
Initials of the caretaker:    
Sex of the caretaker:  (Tick) 





Informed Consent Form (Luganda) 
Interviewee’s Name: ______________________________________________ 
Interviewee Literate (YES/NO) 
(If NO, form will be dictated by interpreter) 
Abaana b’esomero elya University eya Saskatchewan mu Canada mukitongole eky’eddagala 
n’eby’endya (Department of Pharmacy & Nutrition). 
Ntwala omukisa guno okwebaza okumpa omukisa okweyongela okumanya endowooza 
kumukenenya. 
Ekigendererwa ky’omusomo guno kya kutuwa endowooza z’abantu kukukebeza n’okubeera 
n’akawuka kamukenenya mubaana; “musomo gwakunonyereza”. 
Essila mumusomo guno tulitadde kukukulakulanya okumanya ebizibu n’endowooza z’amaka, 
kubikwata kukubera omulamu n’akawuka ka mukenenya mubaana n’abantu abakulu. 
Ekigendererwa kyaffe kwekumanya ebizibu mumaka, ekinatuyamba okutumbuula n’okwongera 
obuyambi n’okutekawo enkyuka kyuka. Tugenda kuyita mubufunze mumusomo 
n’okuwanyisiganya ebilowoozo ebiinaba bivuddemumusomo guno. Tugenda kuwuliriza 
ebikwata ku bantu bangi. Kiyinza obutakuyamba gwe ng’omuntu obwomu, wabula 
gw’omusomo gutukwatako fenna awaamu bwegunaba gumaze okugwa. 
Okwetaba mumusomo gunno kwakyeyagalire era nga kwa bwelele, ngela togusasulira; naye 
tegugenda kukutawanya mumirimu gyo oba pulani yoona gyolina. 
Bwoba t’oyagadde oyinza okutula n’otoddamu kibuuzo kyona bw’ekiba nga tekikuyisizza 
bulungi; naye era oyina orukusa orufuluma kusaawa yoona gyoba oyagadde. 
Omusomo gunno guyinza okumala eddakika nga 30 oba esaawa namba, okusinzira kunsonga 
zetunayogerako. 
Okutekako omukono gwo kubbaluwa eno, kitegeza nti otegedde omusomo kyegutegeza era 
oyina n’omukisa ogubuza ebibuzo byonna byoyagala, era okiriiza okwetaba mumusomo. 
Amaanya _____________________________________ nzikiliza omusomu. 
Enaku z’omwezi ________________________________ 
Thumbprint (If interviewee cannot provide signature) 
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Informed Consent Form (Runyankole) 
 
Interviewee’s Name: ______________________________________________ 
 
Interviewee Literate (YES/NO) 
 
 (If NO, form will be dictated by interpreter) 
 
Nkabacondozi abaana b’eishomero lya University ya Saskatchewan omukitongolo (Department 
of Pharmacy & Nutrition), nitutwara omugisha ogu okwebeebaza okutuha omugisha 
gw’okweyongera kumanya emiturire n’emiteekatekyere y’abantu b’omubyanga bya Uganda 
bitari-bimwe-nabimwe aha bikwatiraine n’akakooko kasirimu. 
Ebigyeendererwa by’omushomo ogu n’okumanya amakuru ahamitekateekyere y’Abanyauganda 
abari kutuura omubyalo, ahakakooko kasirimu, hamwe n’okukyebeza n’okutuura n’akokooko 
aka omubaana. Omushomo ogu gugyendereirwe ahabw’okucondoza. Itwe nk’abeegi 
nituteekateeka ngu omukukoresa omuringo ogu ogw’okucondoza nikiza kwongyera ahakumanya 
kwitu ahakakooko aka: ebizibu ebiri omukukyebeza akakoko kasirimu omubaana n’abantu 
abakuru, hamwe n’ebiri omumaka, nikwo tubaase kutunguura kandi n’okubaasa kutaho 
empinduka omumitwarize egyo. 
Nituza kuraba omubugufu kumanya ebitekateko by’abantu mwena, nabwanyima nituza 
kuhikanisa n’okushugaanisa ebirarugyemu, obwo nitubihandiika aha mpapura. 
Omushomo ogu nigureeba ahaby’abantu baingi barikugamba. Eki nikimanyisa ngu nigubaasa 
obutakuyamba iwe nk’omuntu, beitu kandi omukushuganisa ebiteekateeeko byabaingi, nikiija 
kubaasa kureetaaho okuhweerwa omushomo gwaheza kuhwa. 
Okwija kwawe omumushomo ogu n’okweyendera t’okwokukusiisira emirimu yawe nari 
omwanya gwawe gwabusha. 
Waaba n’oreeba ngu okubaho kwawe nokwokukusisiira n’obasa kureerera okubaho nari 
okutagarukamu ebibuzo ebirikuza kukubuuzibwa. Kandi nabwo, kuwakuteganisibwa 
omumushomo n’obaasa kushohora eshaha yonna obu orikwenda. 
Omushomo nigubaasa kukutwarira edakiika nka makumi ashatu nari obundi guhitsye eshaha 
yoona. 
Okuta omukono gwawe aha baruha egi nikimanyisa ngu n’omanya w’amanya ebigyendererwa 
by’omushomo ogu.  





Ebiro by’okwezi ______________________________________  
Omukono gwawe _______________________________________.  
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Data Collection Questionnaire 
A. BIOGRAPHICAL DATA
1. Place of residence…………………………………… 
2. Class of residence………..Town Dwelling / Country Dwelling 
3. State age of the respondent in years………………….. 
4. Marital Status of respondent: Single, Married, Divorced/Separated, Cohabiting, Widowed,
Other (Specify ___________________________)
5. Would you say it is easy to get HIV testing where you live? Yes/No (Code 1 = Yes; Code 2 =
No)






b. How far is it to your nearest location that offers HIV testing?
____________________________________________________________________
c. How far is it to your nearest location that offers HIV counseling services?
____________________________________________________________________
6. Have you been tested for your HIV status?  Yes/ No  (Code 1= Yes; Code 2 = No)
IF YES: 
i. When were you tested? _____________________________












iii. What is your HIV status? _________________________ 
 
IF NO: 















B. HOUSEHOLD DATA 
1. State the number of people in each age range who are part of your household (including 
yourself) 
a. 0 – 4 years _____________________ 
b. 5 - 9 years _____________________ 




d. 15 – 19 years ___________________ 
e.  20 – 24 years __________________ 
f.  25 – 39 years __________________ 
g. 40 – 59 years ___________________ 
h. 60 – 79 years ___________________ 
i. 80 years and older _______________ 
2. Are all of the children (age 14 and under) in your household under your care? 
___________________ 










5. How much money, per month, would you say the household earns? _________________ 
6. Does your household buy most of its food, or do you grow it yourselves? 
________________________________________________________________________ 





























COMPLETE FOLLOWING SECTION FOR EACH CHILD UNDER INTERVIEWEE’S 
CARE: 
INTERVIEWEE NUMBER (FROM FIRST PAGE) _______________________ 
AGE OF CHILD _______________________ 
ARE YOU THE BIOLOGICAL PARENT OF THIS CHILD? Yes/No (Code 1 = Yes; Code 2 = No) 
IF NO: 
What is your relationship to this child? ___________________________________ 
A. HIV TESTING HISTORY
1. Do you know the HIV status of this child?  Yes/ No (Code 1 = Yes, Code 2 = No)
IF YES: 
a) How old was the child when he or she was tested?
________________________________________________________























B. DRUG THERAPY AND COMPLIANCE DATA (Complete only if child is HIV positive)
1. Please tell us all of the medications the child is currently taking (Recorded by interviewer
in the space below)
2. Please tell us all of the herbal or traditional medicines the child is currently taking
(Recorded by interviewer in the space below)
3. If you can, please tell us what each medication is supposed to do for your child
(Recorded by interviewer in the space below)
4. How often does the child take them? (Recorded by interviewer in the space below)
i. Do they help?  Yes/No.


































6. Do you feel that you need to trick or threaten the child into taking antiretroviral drugs or 
Septrin?  Yes/No (Code 1 = Yes; Code 2 = No) 
IF YES: 






7. Do you ever reward the child under your care for taking their antiretroviral drugs or
Septrin when they are supposed to? Yes/No (Code 1 = Yes; Code 2 = No)
IF YES: 











9. Has the child ever asked you any questions about their HIV-related medication?  Yes/No
(Code 1 = Yes; Code 2 = No)
IF YES: 















10. Has the child ever shown a desire to stop taking their HIV-related medication? Yes/ No 
(Code 1 = Yes; Code 2 = No) 
IF YES: 
a) How old were they when this happened? 
__________________________________________________________
__________________________________________________________ 







11. Was there a time when the child missed a dose of their antiretroviral drugs or their 
Septrin? Yes/No (Code 1 = Yes; Code 2 = No) 
 IF YES: 


















C. CHILD’S HIV LEARNING EXPERIENCE (Complete only if child is HIV positive) 
A. Do you ever talk to the child about HIV? (YES/NO Code 1 = YES, Code 2 = NO) 
If YES: 






b. How old was the child the first time you talked about HIV?  
____________________________________ 
 
c. Listen to the following questions about the child’s HIV knowledge and tell us if 
your child knows the statement or not. If the child knows, say who told them (For 
example, you told them yourself, a family member told them, they learned at 
school, from a doctor, or some other source). Also tell us the age your child 
learned each statement. 
 
d. 
i. Does the child know that he or she has an illness?  
a. Told? [Yes/No] – Circle 
b.  Age: ______________________________ 
c. By whom? __________________________ 





a. Told? [Yes/No] – Circle  
b. Age: _______________________________  
c. By whom? __________________________ 
iii. Does the child know that HIV exists? 
a. Told [YES/NO] – Circle 
b. Age: _______________________________ 
c. By whom? __________________________ 
iv. Does the child know that he or she is HIV positive? 
a. Told? [Yes/No] – Circle  
b. Age: _______________________________  
c. By whom? __________________________ 
v. People with HIV may have a harder time fighting off sicknesses  
a. Told? [Yes/No] – Circle  
b. Age: _______________________________  
c. By whom? __________________________ 
vi. A person with HIV can develop AIDS  
a. Told? [Yes/No] – Circle 
b.  Age: _______________________________ 
c.  By whom? __________________________ 
vii. A person with AIDS has an extremely hard time fighting off other sicknesses 
a. Told? [Yes/No] – Circle  
b. Age: _______________________________ 
c. By whom? __________________________ 
viii. Certain HIV medications can help someone who is HIV positive be stronger 
and healthier 
a. Told? [Yes/No] – Circle  
b. Age: _______________________________  
c. By whom? __________________________ 
ix. Certain HIV medications can delay a person with HIV from developing 
severe illness (AIDS)  
a. Told? [Yes/No] – Circle  
b. Age: _______________________________  
c. By whom? __________________________ 
x. Certain HIV medications must be taken for the rest of a person’s life 
a. Told? [Yes/No] – Circle  




c. By whom? __________________________ 
xi. Missing doses of certain HIV medications can make them less effective 
a. Told? [Yes/No] – Circle  
b. Age: _______________________________ 
c.  By whom? __________________________ 
xii. HIV can be spread through contact with blood 
a. Told? [Yes/No] – Circle  
b. Age: _______________________________ 
c. By whom? __________________________ 
xiii. HIV can be spread through sex 
a. Told? [Yes/No] – Circle  
b. Age: _______________________________ 
c.  By whom? __________________________ 
xiii. HIV can be spread from a positive mother to her child through birth 
a. Told? [Yes/No] – Circle  
b. Age: _______________________________  
c. By whom? __________________________ 
xiv. A HIV positive woman who is nursing may spread HIV to the infant 
a. Told? [Yes/No] – Circle  
b. Age: _______________________________  
c. By whom? __________________________ 
 
If NO:  
















D. DISCLOSURE BEHAVIOURS (Complete only if child is HIV positive) 
1. Please pick the following statement that best describes what you told the child about their 
HIV infection (Circle appropriate choice):  
i. They were told that they have HIV (FULL DISCLOSURE) 
ii. They were told that they were sick but were not told what illness they had 
(PARTIAL DISCLOSURE) 
iii. They have been told nothing at all (NO DISCLOSURE) 
 (CODE 1 = FULL DISCLOSURE, CODE 2 = PARTIAL DISCLOSURE,  
  CODE 3 = NO DISCLOSURE) 
 
IF FULL DISCLOSURE: 
 
a. How old was the child when they were told? ______________________ 
 
b. Were you the person who told them that they had HIV? Yes/No (Code 1 = Yes; 
Code 2 = No) 
i. IF YES: 






b. Did anybody help you to plan what to say to the child? Yes/No 
(Code 1 = Yes; Code 2 = No) 
IF YES: 
1. Who helped you? (Circle all who apply: Family, 
Friends, School, HIV Counselor, Doctor, Nurse, 
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Support Group, Religious Leader, Other 
_______________) 
IF NO: 
a. Who told them? ______________________________________






































h. Does the child know how they got HIV? (Yes/No: Code 1 = YES, Code 2 = 
NO) 
IF YES: 















iii. How old were they at the time? 
_________________________________________________________ 






i. Do you think telling the child that they were positive when and how you did 
was the right decision? Yes/No (Code 1 = Yes; Code 2 = No) 







j. Did you at first only tell them that they were sick? Yes/No (Code 1 = Yes; 
Code 2 = No)  
IF YES: Complete “IF PARTIAL DISCLOSURE” section as well 
 
IF PARTIAL DISCLOSURE: 
 
a. How old was the child when they were told?_____________________________ 
b. Were you the person who told them that they had HIV? Yes/No (Code 1 = Yes; 
Code 2 = No) 
1. IF YES: 









b. Did anybody help you plan what you were going to tell the 
child? If so, who?: 
____________________________________________________
____________________________________________________  







d. Did anybody help you decide what to say to the child? Yes/No 
(Code 1 = Yes, Code 2 = No) 
 
IF YES: 
1. Who helped you? (Circle all that apply: Family, Friends, 
Teachers, HIV Counselor, Doctor, Nurse, Support group, 




1. Who told them? 
______________________________________ 
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IF NO DISCLOSURE: 









c. When do you think would be the best age to tell him or her?
d. __________________________________________________________
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1. Have you disclosed the positive status of a child under your care to anyone else?  Yes/No
(Code 1 = Yes; Code 2 = No)
a. If YES















E. ATTITUTES TOWARDS DISCLOSURE 
1. I am now going to read several general statements about HIV. Tell me whether you think they are 
mostly true or mostly untrue. If possible, tell me what made you answer the way you did: 
a. An HIV positive child may be discriminated against in the community if the community 
learned of their HIV positive status 
________________________________________________________________________
________________________________________________________________________ 
b. An HIV positive child will have a good attitude toward their medication if they are aware 
of their positive status 
________________________________________________________________________
________________________________________________________________________ 
c. An HIV positive child will accidentally disclose their positive status to the rest of the 
community if the child is informed of their HIV status at too young of an age 
________________________________________________________________________
________________________________________________________________________ 
d. An HIV positive child would feel that their life is without hope if they are informed of 
their HIV status 
________________________________________________________________________
________________________________________________________________________ 
e. An HIV positive child would feel that their future is limited if they are told 
________________________________________________________________________
________________________________________________________________________ 









Appendix B: Changes to Research Proposal, Interview Questionnaire and Informed 
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Appendix C: Guide for Interview Translators 
Guide for Interview Translators 
Introduction 
Congratulations on your decision to act as a translator for this research study.  As a translator, you are a 
vital link between the researcher and the interviewees, allowing them to communicate in a clear manner 
in spite of language barriers that would otherwise make discussion impossible. 
Because of your vital role in the research process, the quality of your work will have a direct impact on 
the quality of the research provided; Even an extremely well-designed study will produce useless or 
misleading results if the translators are not properly instructed.  
With this in mind, below please find a brief guide on the most important aspects of acting as a translator. 
General Responsibilities 
As a translator, you will accompany a researcher who is would ordinarily be conducting one-on-one 
interviews with volunteers. The researcher will not be adequately proficient in Runyankole or Luganda to 
conduct the interviews in these languages, and the interviewees will often not be sufficiently proficient in 
English to conduct the interview in that language.  You will translate the questions and answers of the 
interview in order to facilitate the process. 
During the interview, the researcher will direct questions directly at the interviewee. Once a question has 
been asked, you will repeat the question exactly as it was asked in the interviewee’s language of choice. 
When the interviewee answers, you will translate their response exactly as it was answered into English. 
In the event that a response is excessively long, it is acceptable (in fact, encouraged) that you get the 
interviewee to pause while you translate what has initially been said to the researcher. Once the first part 
has been translated, prompt the interviewee to continue. 
If you do not understand what an interviewee is saying, you may ask them to repeat themselves. It is 
important, however, that you include your question when translating the full exchange to the researcher. 
Interviews will usually be recorded via audio tape or digital audio. In the event that an interviewee 
withholds consent to be recorded in such a manner, the researcher will need to record responses on paper. 
Obviously, the translation of such interviews will be much slower, and it may be necessary for you to 
prompt the interviewee to pause more frequently during long responses than you would if the interview is 
being recorded. 
Confidentiality 
As a translator, you will be in a position to learn extremely private information about the interviewee’s 
health status and personal life. It is essential that all information you obtain in the course of the interviews 
remain between you, the researcher, and the interviewee. Any sharing of information obtained during the 
interview with anybody else, either verbally or in writing, will result in the translator’s immediate 
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termination from the study. Legal action may also be taken where applicable against anybody responsible 
for confidential information being illegally shared.   
Before you assist in your first interview, you will be required to sign a confidentiality agreement. This 
agreement states that you are aware of the confidentiality requirements and agree to not share any 
information you obtain in the study with anybody outside of the study, for any reason. 
Similarly, you may find that an interviewee is somebody who you personally know. If this situation 
arises, you must inform the researcher before the interview begins. Depending on the nature of the 
relationship between you and the interviewee, an alternate translator may be selected. This will be at the 
discretion of the researcher who is to conduct the interview. 
Precision 
The ultimate goal of this research is to examine the experiences of a number of people in order to see 
what patterns, if any, exist. In order for research to be considered valid, each interview must be similar. 
That is, each interviewee must be asked the same questions in the same manner, and their responses must 
be recorded in a consistent manner. Simply put, you must be sure to translate the interview questions in 
an identical manner for every interview that you do. 
When translating interviewee’s responses to English, it is important that you translate what was said as 
precisely as possible. Below are some examples of errors that reduce the precision of a translator’s work, 
and ways that they can be avoided: 
a. Additions
Additions happen when a translator reports something that the interviewee never actually 
said. Often, additions occur when the translator tries to clarify something said by the 
interviewee, in order to make things clearer for the researcher. Although done with the best of 
intentions, these additions will add the translator’s own biases into the responses and make 
the data less valid. Concentrate on translating exactly what was said – if the interviewer 
wishes something to be clarified, they will ask a follow-up question to the interviewee, 
through you. 
b. Omissions
Omissions happen when something said by the interviewee is not translated. Not everything 
said by an interviewee will be relevant for the purpose of the study. Even so, it is important to 
translate everything said as precisely as possible and let the researcher decide what is relevant 
or not. An example of this would be if an interviewee is asked a “yes or no” question, but 
responds by telling a long anecdote. The translator, in an effort to keep the responses brief, 
tells the researcher only the ‘yes or no’ part of the response, ignoring the bulk of what was 
said. Although you may be tempted to shorten the response to just the requested yes or no, 
doing so harms the validity of the study. 
If you find that an interviewee’s response is significantly long, it is best to ask the interviewee 
to pause while you translate what you have heard so far to the researcher. Once the researcher 
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has recorded what you have initially translated, prompt the interviewee to continue. By 
handling long responses in this manner, the odds of something being accidentally omitted are 
reduced. 
c. Substitutions
Similar to additions, substitutions occur when a translator changes what is said by the 
interviewee in an effort to make things clearer for the researcher. Although done with good 
intentions, it is important for translators to translate exactly what was said, rather than putting 
the responses into their own words. 
Substitutions can also occur when a translator is translating a long response from an 
interviewee, when items said at the start of the response become difficult to recall precisely. 
As mentioned above, it is best to pause an interviewee during an overly-long response, 
translate what was said so far, and then prompt the interviewee to continue. 
d. Condensations
Similar to omissions, condensations occur when a translator shortens what is said by an 
interviewee in an effort to make things more concise or brief for the researcher. Much like the 
other actions described above, condensing an interviewee’s response ultimately harms the 
study’s results and the practice should be avoided. 
e. Role Exchanges
Role exchanges occur when a translator replaces one person’s role in a response with that of 
another person. For example, if the interviewee said that she was the caregiver of her sister’s 
HIV positive child and the translator mistakenly said that the caregiver was the child’s 
mother, this would introduce incorrect information into the study’s results.  
Mock Interview 
Prior to performing your first interview in the field, you and another translator will have the chance to 
practice your skills in at least one mock interview. The goal of the mock interview is to ensure that each 
translator is capable and confident in their role before data collection begins. 
During the mock interview, one translator will act as the interviewee, and use a written outline to answer 
interview questions in runyakole or luganda. The other translator will assist the researcher by translating 
during the interview. After one interview, the translators will switch roles, with the other translator 
pretending to be the interviewee, answering the questions in either runyankole or luganda according to a 
different outline. 
Once both mock interviews are completed, the two translators and the researcher will discuss the 
responses and evaluate how accurately each interview was translated, and determine if any improvements 
can be made. 
Confidentiality Agreement 
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I, the undersigned, hereby acknowledge that the interaction between interviewees, researchers, and myself 
is confidential in nature. Further, I agree to respect and maintain the confidentiality of all information 
exchanged during the interview. I acknowledge that any sharing of such information to any party outside 
of those present at the actual interview (myself, the researcher, and the interviewee), for any reason and 
by any method of communication, is a violation of that confidentiality. I am aware that, should I violate 
the confidentiality of the information, either intentionally or accidentally, I will be immediately 
terminated in my role of translator. Further, I may be subject to legal action pursuant to such a breach of 
confidentiality. 
Name (Print) ___________________________________________ 
Signature ______________________________________________ 
Date__________________________________________________ 
